Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DMACNASDAQ:KRRONASDAQ:NMRANASDAQ:XFOR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDMACDiaMedica Therapeutics$3.65+2.2%$3.97$2.83▼$6.82$156.51M1.1799,685 shs153,019 shsKRROKorro Bio$12.90-1.5%$14.18$10.29▼$98.00$121.13M2.43106,594 shs33,300 shsNMRANeumora Therapeutics$0.81+3.7%$0.77$0.61▼$17.19$131.18M2.751.53 million shs389,866 shsXFORX4 Pharmaceuticals$1.97-0.8%$3.19$1.81▼$26.96$11.38M0.54133,066 shs380,089 shsA Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDMACDiaMedica Therapeutics+2.24%-4.20%-11.41%+4.29%+24.15%KRROKorro Bio-1.45%+4.54%+8.13%-10.29%-66.34%NMRANeumora Therapeutics+3.68%+1.45%+9.14%+10.12%-91.69%XFORX4 Pharmaceuticals-0.76%-1.75%-50.38%-69.48%-88.40%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationDMACDiaMedica Therapeutics1.0293 of 5 stars3.51.00.00.00.60.00.0KRROKorro Bio2.5525 of 5 stars3.63.00.00.02.70.00.6NMRANeumora Therapeutics2.6169 of 5 stars3.11.00.00.02.82.51.3XFORX4 Pharmaceuticals4.7223 of 5 stars3.52.00.04.61.13.32.5Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDMACDiaMedica Therapeutics 3.00Buy$8.00119.18% UpsideKRROKorro Bio 3.29Buy$102.43694.02% UpsideNMRANeumora Therapeutics 2.22Hold$9.291,044.97% UpsideXFORX4 Pharmaceuticals 3.00Buy$72.333,581.09% UpsideCurrent Analyst Ratings BreakdownLatest XFOR, KRRO, DMAC, and NMRA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/29/2025DMACDiaMedica TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.005/13/2025KRROKorro BioChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.00 ➝ $25.005/13/2025KRROKorro BioOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$155.00 ➝ $90.005/13/2025NMRANeumora TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.005/8/2025KRROKorro BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$115.00 ➝ $100.005/2/2025XFORX4 PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$1.50 ➝ $7.004/29/2025KRROKorro BioCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy4/28/2025KRROKorro BioCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$74.004/16/2025KRROKorro BioChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$25.004/10/2025NMRANeumora TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.00(Data available from 7/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDMACDiaMedica TherapeuticsN/AN/AN/AN/A$0.95 per shareN/AKRROKorro Bio$2.27M53.36N/AN/A$17.12 per share0.75NMRANeumora TherapeuticsN/AN/AN/AN/A$1.78 per shareN/AXFORX4 Pharmaceuticals$2.56M4.44N/AN/A$3.90 per share0.50Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDMACDiaMedica Therapeutics-$24.44M-$0.64N/AN/AN/AN/A-61.35%-55.53%8/6/2025 (Estimated)KRROKorro Bio-$83.58M-$9.44N/AN/AN/AN/A-51.64%-37.94%8/12/2025 (Estimated)NMRANeumora Therapeutics-$243.79M-$1.61N/AN/AN/AN/A-84.79%-77.57%8/5/2025 (Estimated)XFORX4 Pharmaceuticals-$37.45M$2.140.92N/AN/A46.54%-181.56%-54.36%8/6/2025 (Estimated)Latest XFOR, KRRO, DMAC, and NMRA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025DMACDiaMedica Therapeutics-$0.18-$0.18N/A-$0.18N/AN/A5/12/2025Q1 2025NMRANeumora Therapeutics-$0.40-$0.42-$0.02-$0.42N/AN/A5/7/2025Q1 2025KRROKorro Bio-$2.60-$2.49+$0.11-$2.49$0.13 million$2.55 million5/1/2025Q1 2025XFORX4 Pharmaceuticals-$4.13$0.04+$4.17$0.04$7.03 million$28.81 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDMACDiaMedica TherapeuticsN/AN/AN/AN/AN/AKRROKorro BioN/AN/AN/AN/AN/ANMRANeumora TherapeuticsN/AN/AN/AN/AN/AXFORX4 PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDMACDiaMedica TherapeuticsN/A8.028.02KRROKorro BioN/A9.419.41NMRANeumora TherapeuticsN/A8.988.98XFORX4 Pharmaceuticals3.303.703.58Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDMACDiaMedica Therapeutics10.12%KRROKorro Bio13.18%NMRANeumora Therapeutics47.65%XFORX4 Pharmaceuticals72.03%Insider OwnershipCompanyInsider OwnershipDMACDiaMedica Therapeutics7.30%KRROKorro Bio4.60%NMRANeumora Therapeutics26.80%XFORX4 Pharmaceuticals2.37%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDMACDiaMedica Therapeutics2042.88 million39.75 millionOptionableKRROKorro Bio709.39 million8.96 millionNo DataNMRANeumora Therapeutics108161.75 million118.40 millionOptionableXFORX4 Pharmaceuticals805.79 million5.65 millionOptionableXFOR, KRRO, DMAC, and NMRA HeadlinesRecent News About These CompaniesX4 Pharmaceuticals, Inc. (XFOR) - Yahoo FinanceJuly 3 at 11:17 PM | finance.yahoo.comX4 Pharmaceuticals Inc News (XFOR) - Investing.comJuly 2 at 11:54 AM | investing.comXFOR X4 Pharmaceuticals, Inc. - Seeking AlphaJune 26, 2025 | seekingalpha.comX4 Pharmaceuticals Presents Positive Phase 2 Chronic Neutropenia Trial Data in Poster Presentations at the 30th Annual Congress of the European Hematology Association (EHA)June 16, 2025 | globenewswire.comX4 Pharmaceuticals Gets Fast Track Regulatory Designation for Neutropenia DrugJune 10, 2025 | marketwatch.comX4 Pharmaceuticals gains on fast-track designation for mavorixafor for treatment of chronic neutropeniaJune 10, 2025 | msn.comX4 Pharmaceuticals Granted Fast Track Designation for Mavorixafor for the Treatment of Chronic Neutropenia by U.S. FDAJune 10, 2025 | globenewswire.comX4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 2, 2025 | globenewswire.comX4 Pharmaceuticals Reports Positive Phase 2 Trial Results for Mavorixafor in Chronic Neutropenia, Accepted for Presentation at EHA CongressMay 16, 2025 | nasdaq.comX4 Pharmaceuticals Announces Upcoming Presentation of Phase 2 Chronic Neutropenia Trial Data at the 30th Annual EHA CongressMay 14, 2025 | globenewswire.comX4 Pharmaceuticals Inc (XFOR) Q1 2025 Earnings Call Highlights: Progress in Maverick 4 ...May 2, 2025 | finance.yahoo.comX4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Q1 2025 Earnings Call TranscriptMay 2, 2025 | insidermonkey.comX4 Pharmaceuticals, Inc. (XFOR) Q1 2025 Earnings Call TranscriptMay 1, 2025 | seekingalpha.comX4 Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate UpdatesMay 1, 2025 | finance.yahoo.comX4 Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate UpdatesMay 1, 2025 | globenewswire.comX4 Pharmaceuticals Q1 2025 Earnings PreviewApril 30, 2025 | msn.comX4 Pharmaceuticals Analyst RatingsApril 30, 2025 | benzinga.comEarnings Preview For X4 PharmaceuticalsApril 30, 2025 | benzinga.comWhy X4 Pharmaceuticals, Inc. (XFOR) is Surging in 2025April 30, 2025 | insidermonkey.comX4 Pharmaceuticals To Implement 1-for-30 Reverse Stock Split On April 28April 26, 2025 | nasdaq.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeXFOR, KRRO, DMAC, and NMRA Company DescriptionsDiaMedica Therapeutics NASDAQ:DMAC$3.65 +0.08 (+2.24%) Closing price 07/3/2025 03:41 PM EasternExtended Trading$3.72 +0.07 (+2.03%) As of 07/3/2025 04:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease. The company also develops DM300, which is in preclinical stage for the treatment of severe inflammatory diseases. In addition, it develops treatment for neurological disease. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.Korro Bio NASDAQ:KRRO$12.90 -0.19 (-1.45%) As of 07/3/2025 03:01 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Korro Bio, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, OPERA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe alcohol-associated hepatitis, and other subsets of pain. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.Neumora Therapeutics NASDAQ:NMRA$0.81 +0.03 (+3.68%) Closing price 07/3/2025 03:14 PM EasternExtended Trading$0.81 +0.00 (+0.25%) As of 07/3/2025 04:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.X4 Pharmaceuticals NASDAQ:XFOR$1.96 -0.02 (-0.76%) Closing price 07/3/2025 03:56 PM EasternExtended Trading$1.92 -0.05 (-2.29%) As of 07/3/2025 04:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia. The company is also developing X4P-003, a CXCR4 antagonist for the treatment of CXCR4 dependent disorders and primary immunodeficiencies; and X4P-002, a CXCR4 antagonist for the treatment of blood-brain barrier diseases. It has a license agreement with Abbisko Therapeutics Co Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Rocket Lab: Latest Catalysts Bolster the Bull Case Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
